Management of rapid alerts arising from quality defects risk assessment
Submitted by Anonymous (not verified) on 28 August 2024 - 13:57
Management of rapid alerts arising from quality defects risk assessment
History of changes to the compilation of procedures
Submitted by Anonymous (not verified) on 28 August 2024 - 13:56
History of changes to the compilation of procedures
EVVet3 EVWeb Production - Release notes
Submitted by Anonymous (not verified) on 28 August 2024 - 13:29
EVVet3 EVWeb Production - Release notes
Fourth European Medicines Agency (EMA) and Nuclear Medicines Europe bilateral meeting, Online, 14 June 2024
Submitted by Anonymous (not verified) on 28 August 2024 - 13:23
Fourth European Medicines Agency (EMA) and Nuclear Medicines Europe bilateral meeting, Online, 14 June 2024
Third European Medicines Agency (EMA) and MedTech Europe bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, 2 July 2024
Submitted by Anonymous (not verified) on 28 August 2024 - 13:18
Third European Medicines Agency (EMA) and MedTech Europe bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, 2 July 2024
General conditions of purchase orders
Submitted by Anonymous (not verified) on 28 August 2024 - 13:02
General conditions of purchase orders
Timetable: Type II variation and worksharing application monthly assessment
Submitted by Anonymous (not verified) on 28 August 2024 - 12:00
Timetable: Type II variation and worksharing application monthly assessment
Shortage of Actilyse (alteplase) and Actilyse Cathflo (alteplase)
Submitted by Anonymous (not verified) on 28 August 2024 - 8:21
Shortage of Actilyse (alteplase) and Actilyse Cathflo (alteplase)
Shortage of Metalyse (tenecteplase)
Submitted by Anonymous (not verified) on 28 August 2024 - 8:20
Shortage of Metalyse (tenecteplase)
Human medicines European public assessment report (EPAR): Vanflyta, quizartinib, Date of authorisation: 06/11/2023, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 27 August 2024 - 14:14
Human medicines European public assessment report (EPAR): Vanflyta, quizartinib, Date of authorisation: 06/11/2023, Revision: 2, Status: Authorised